Figure 1. 237CART cells eradicate Tn-positive human cancers regardless of murine Tn-PDPN expression.
Survival of NSG mice bearing 2-week-old established systemic Jurkat leukemia (Pdpn-, COSMC-, and CD19-transduced, and the parental cell line) that were treated with 5 × 106 237CART cells, 5 × 106 CD19CART cells, or an equal volume of PBS (n = 3 or 4 mice per treatment group from at least 3 independent experiments as indicated in the figure). Disease progression was monitored weekly by bioluminescent imaging. The survival difference of the animals between the 2 groups was analyzed by log-rank Mantel-Cox test. **P ≤ 0.01.